番茄社区app

Meeting Coverage >

ASH: Hematology

Novel Sickle Cell Tx Shows Promise for Pain Crises

Monoclonal antibody tied to lower incidence of adverse events

OncoBlog: Driving the CAR to a Cancer Cure?

Is immunotherapy with chimeric antigen receptor (CAR)-directed T cells the "next big thing" in oncology? Presentations and discussion at a recent conference suggest the technology has considerable promise -- but will it qualify as a breakthrough? OncoBlog is a blog by the Medpage Today staff for readers with an interest in oncology. This post comes from Charles Bankhead.

Gene Therapy Works in SCID With No Risk of Leukemia

NEW ORLEANS -- Genetic therapy appeared to restore the immune system of patients with X-linked severe combined immunodeficiency (SCID), but without leading to leukemia as a side effect, researchers reported here.

Infection High in Myeloma, with High Mortality

ATLANTA -- More than a fifth of patients with multiple myeloma died of infection within a year of diagnosis, Swedish investigators reported here.

Oral Azacitidine Safe, Effective in Low-Risk MDS

ATLANTA -- Oral azacitidine (Vidaza) given for up to 21 days per 4-week cycle for myelodysplastic syndrome appeared safe and effective in patients with lower-risk disease, a researcher said here.

New Combo Replaces CHOP for Lymphoma

ATLANTA - The combination chemotherapy known as CHOP, used for nonHodgkin's lymphoma, is rapidly being replaced by bendamustine (Treanda), frequently combined with rituximab (Rituxan), researchers reported.

Children OK with Long-Term Exjade

ATLANTA -- Children with thalassemia and treated with the anti-iron overload drug deferasirox (Exjade) appear to tolerate the treatment for at least as long as 3 years while serum iron levels fell, researchers said here.

Extended Apixaban Stops VTE Recurrence

ATLANTA -- Apixaban taken for an additional year after standard venous thromboembolism (VTE) treatment reduced recurrent events in a placebo-controlled trial, researchers said.

Polycythemia Vera Better with Low Hematocrit

ATLANTA -- Maintaining patients with polycythemia vera at hematocrit levels below 45% reduced thrombotic complications without increasing rates of other serious adverse events.

ASH: Drugs Effective in Chronic ITP Not Appropriate as First-Line Treatment

SAN FRANCISCO -- Rituximab (Rituxan) and eltrombopag (Promacta) are "too aggressive and too expensive" for use as first-line therapies against chronic idiopathic thrombocytopenic purpura, agreed participants in an exclusive 番茄社区app roundtable discussion.